June 3, 2025 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against ABBV

Core Viewpoint - The article discusses a class action lawsuit against Cerevel Therapeutics Holdings, Inc. related to alleged misleading statements and omissions regarding AbbVie's acquisition interest, which impacted the stock price during a secondary offering [1][2]. Group 1: Allegations and Impact - Cerevel's October 16, 2023 secondary stock offering documents allegedly omitted material facts about AbbVie's interest in acquiring Cerevel at a significantly higher price than the offering price of $22.81 per share, leading to an artificially deflated stock price until the merger announcement [2]. - Bain Capital, Cerevel's controlling shareholder, reportedly acquired shares at the depressed price while possessing nonpublic information about AbbVie's acquisition interest, resulting in a windfall of over $120 million when AbbVie agreed to acquire Cerevel for $45 per share on December 6, 2023 [2]. - The January 18, 2024 Proxy statement from Cerevel allegedly misled investors regarding the nature and timing of AbbVie's interest in the company [2]. Group 2: Class Action Details - The class period for the lawsuit includes individuals who sold or disposed of Cerevel stock from October 11, 2023, to August 1, 2024, and those who held shares as of January 8, 2024, entitled to vote on the merger [1]. - The deadline for shareholders to register for the class action is June 3, 2025, and there is no cost or obligation to participate [3]. - Registered shareholders will receive updates through a portfolio monitoring software throughout the case lifecycle [3]. Group 3: Law Firm Information - The Gross Law Firm is a nationally recognized class action law firm focused on protecting investors' rights against deceit and fraud, ensuring companies adhere to responsible business practices [4].